ArticleMolecular biology reports2025
High frequency and prognostic significance of TP53 promoter methylation in Pakistani glioblastoma patients.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma multiforme (GBM) is the most aggressive brain tumor, with poor overall survival (OS). TP53, a key tumor suppressor gene, is frequently altered in GBM, but the prognostic relevance of its promoter methylation has not been investigated in the Pakistani population.
methodsIn this retrospective study, TP53 promoter methylation was assessed in 48 primary GBM patients and 60 healthy controls using methylation-sensitive high-resolution melting analysis. Associations with clinicopathological features and treatment modalities were assessed using Fisher's exact/Chi-square test. OS was estimated with Kaplan-Meier survival analysis and Cox proportional hazard regression was performed as exploratory analysis.
resultsTP53 promoter methylation was detected in 72.9% (35/48) of GBM patients but in none of the controls. TP53 methylation showed no significant difference across clinicopathological variables or improved OS. However, patients with unmethylated TP53 who received post-surgical chemoradiotherapy had significantly longer OS (65.6 months; 95% CI: 60.6-70.5; P = 0.040) compared with methylated cases (19.2 months; 95% CI: 9.9-28.4). The effect was more pronounced in patients with concurrent MGMT methylation (unmethylated TP53: 65.6 months; 95% CI: 60.6-70.5 vs. methylated TP53: 13.2 months; 95% CI: 9.2-17.2; P = 0.018).
conclusionThis is the first study to report frequent TP53 promoter methylation in Pakistani GBM patients. Our exploratory findings suggest that combined MGMT methylation and TP53 unmethylation may confer a survival advantage. Larger prospective studies are needed to validate these findings before clinical application.
Indexed as
Identifiers
41283930What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.